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Abstract 
We have investigated the binding of human tissue kallikrein and the corresponding proenzyme to isolated human lymphocytes and neutrophils, 
respectively, by the means of steady-state binding assays. It was demonstrated that only prokallikrein bound to washed neutrophils in a time- 
dependent, specific and saturable manner, whereas in vitro binding of activated kallikrein to neutrophils or lymphocytes could be excluded. Our data 
provide strong evidence for the specific interaction of prokallikrein with intact human neutrophils and indicate a neutrophil surface binding site for 
the tissue kallikrein precursor which could be involved in kallikrein endocytosis and selective prokallikrein-to-kallikrein conversion. 
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1. Introduction 
Human tissue kallikreins (EC 3.4.21.35) comprise a 
subfamily of trypsin-like glycoproteins of closely related 
structure which share common biological features, espe- 
cially the highly selective kininogenase activity. Limited 
proteolysis of their endogenous ubstrates high and low 
molecular weight kininogen (HMWK and LMWK) lib- 
erates the vasoactive decapeptide kallidin (Lys-bradyki- 
nin), which is involved in the regulation of local blood 
flow and vascular permeability [l]. The hitherto charac- 
terized tissue kallikreins, called urinary, pancreatic and 
salivary-gland kallikrein, are expressed by a common 
gene, which encodes a pre-pro-enzyme with a 17-amino 
acid signal peptide, that is subsequently split off during 
protein translocation within the cells. The originating 
enzymatically inactive prokallikrein carries an N-termi- 
nal activation peptide of seven amino acids in length with 
a sequence motif, which is identical in all kallikrein spe- 
cies examined so far [2]. Cleavage of the propart oc- 
curred by limited proteolysis of the precursor, which 
could be achieved in vitro by plasma kallikrein, plasmin, 
thermolysin and trypsin to yield mature kallikrein [3]. 
However, these proteinases possess no in vivo signifi- 
cance for the proenzyme conversion, leaving the physio- 
logical activation process yet unidentified. 
The active proteinase and varying proportions of 
prokallikrein together are present in a variety of tissues 
like kidney, pancreas and salivary glands, but also found 
in their secretions and different body fluids, namely 
plasma, synovial and bronchoalveolar lavage fluid [4]. 
Recently, the localisation of tissue kallikrein in cytoplas- 
mic granules of circulating neutrophils has been demon- 
strated in normal human blood and bone marrow by 
immunocytochemical techniques, whereas the enzyme 
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was not detectable in eosinophils, lymphocytes, macro- 
phages, mega-karyocytes and platelets [5]. The func- 
tional importance of this discovery is illustrated by the 
specific attachment of both HMWK and LMWK [6,7], 
as well as plasma prekallikrein [8], on the exterior surface 
of human neutrophils, displaying a spatial relationship 
of substrates and corresponding proteinases involved in 
kinin liberation. 
Whereas the presence of tissue kallikrein in neutro- 
phils has been reported, the source of this kininogenase 
remains unclear. Contradictory discussion arouses 
whether the neutrophil tissue kallikrein was due to in situ 
synthesis of a kallikrein precursor [4] or to the capture 
of mature kallikrein by endocytosis from plasma after 
cell binding [9]. To prove the latter hypothesis, we have 
studied the ability of human salivary-gland kallikrein, 
that is in the zymogen or activated form, to interact with 
isolated human neutrophils. In addition, the identifica- 
tion of such binding sites is a prerequisite which provides 
new insights into the prokallikrein conversion and func- 
tion of tissue kallikrein in neutrophils during physiolog- 
ical and pathological events. 
2. Materials and methods 
2.1. Materials 
Human recombinant salivary-gland prokallikrein (M, = 35,000) was 
purified from the previously described pVLKA56-based baculovirus 
expression system [2]. Trypsin activation of the proenzyme [3] and 
separation of the activation peptide by gel filtration on a Superose 12 
HR lo/30 column (Pharmacia) using 10 mM sodium phosphate, 100 
mM NaCl, pH 7.2 with a flow rate of 0.3 ml/min yielded mature 
salivary-gland kallikrein (M, = 33,000). Human urinary kallikrein 
(M, = 41,000) was a kind gift from R. Geiger (Munchen). 
2.2. Isolation of human neutrophils and lymphocytes 
Separation of blood cells occured by density centrifugation on Neu- 
trophil Isolation Medium (NIM; Paesel + Lorei) using a modified ver- 
sion of the manufacturer’s recommendations. Briefly, whole blood of 
healthy donors was collected by venipuncture into l/49 volume 10% 
EDTA and gently layered in 7 ml-fractions over 4 ml NIM followed 
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by centrifugation at 400 x g for 30 min at 20°C. The lymphocyte- 
containing plasma of the upper band and the neutrophil-enriched frac- 
tion of the lower band were aspirated separately and diluted with equal 
volumes Krebs-Ringer buffer (121 mM NaCl, 4.9 mM KCl, 16.5 mM 
Na,HPO,, 1.2 mM KH,PO,, 1.2 mM MgSO,, pH 7.4) to remove NIM- 
traces by sedimentation at 450 x g for 10 min. Cell pellets were washed 
twice with RPM11640 medium supplemented with 20% fetal calf serum, 
resuspended in the same medium and used within 6 h after preparation. 
This procedure yielded approximately 6x lo6 cells/ml whole blood, 
for neutrophils and lymphocytes respectively, as counted in a Thoma 
chamber. The cell viability was over 97% assessed by the Trypan blue 
exclusion test. 
2.3. Kallikrein binding studies 
Before the binding studies, neutrophils and lymphocytes were 
washed twice with Krebs-Ringer buffer containing 0.05% Brij 35 and 
resuspended in the same buffer at a final concentration of 3 x lo7 
cells/ml. Incubation of the cells occurred at 37’C with increasing 
amounts of different tissue kallikrein samples in a total assay volume 
of 300 ~1. The reaction was terminated at the indicated periods by 
centrifugation for 10 min at 5000 rpm in a microfuge, and the superna- 
tant was analyzed for unbound kallikrein species by an enzymatic assay 
with the fluorogenic peptide substrate H-prolyl-phenylalanyl-arginine- 
7-amido-4-methvlcoumarin (H-Pro-Phe-Arg- AMC; Bachem) accord- 
ing to [lo] by means of a‘Perkin Elmer-LS 50 ~p~trofl~o~eter 
(II,, = 380 nm; a,,,, = 460 nm). The amidolytic kallikrein activity was 
measured irectly or after trypsin activation of the proenzyme. Total 
binding was calculated as the difference between the kallikrein activity 
of cell-free reaction mixtures and the corresponding binding assays. The 
results are represented in arbitrary units (AU) where one unit is defined 
as that amount of enzyme which releases 2 pmol AMC/s under the 
described conditions. 
3. Results and discussion 
The preparation of human salivary-gland prokal- 
likrein expressed in recombinant baculovirus-infected in- 
sect cells together with in vitro proenzyme conversion 
has enabled our laboratory to investigate the physiolog- 
ical function of the tissue kallikrein precursor which is 
not interfered with by trace amounts of proteinases in 
prokallikrein fractions from natural sources 1121. The 
recombinant material displayed full biological activity 
and recognition of all three glycosylation sites [2] which 
might be essential for protein-11 interaction. 
Cell-binding experiments with different components of 
the kallikrein-kinin system have been performed in situ 
by immunolocalization [5,7-91 or in vitro by binding 
assays with radiolabeled ligands [6,11]. This study intro- 
duces an e~mati~ assay based upon the selective tissue 
kallikrein substrate H-Pro-Phe-Arg-AMC [lo] to moni- 
tor the amidolytic activity of unbound kallikrein using 
sensitive fluorescence measurements. To assess misrepre- 
sentations of fluorescence intensity which might occur by 
the kallikrein content of freshly isolated cells, washed 
neutrophils alone at a concentration of 3 x 10’ cells/ml 
were incubated under assay conditions, and the ami- 
dolytic kallikrein activity in the su~matant was meas- 
ured directly or after trypsination to cover prokallikrein. 
Values amounted to 0.02 AU and to 0.04 AU in the latter 
case (data not shown) which were subtracted as back- 
ground from kallikrein activity in cell binding experi- 
ments. Cell viability was not affected by the assay condi- 
tions as can be proved, thus excluding the release of 
kallikrein from cell lysis. 
Further investigations were conducted to ascertain 
whether the external membrane of neutrophils contains 
unoccupied binding sites for pro- or mature kallikrein. 
Increasing con~ntrations of recombinant pro-kal- 
likrein, recombinant kallikrein and urinary kallikrein, 
respectively, were added to washed human neutrophils 
and bound kallikrein species quantified by differential 
amidolytic assays (Fig. 1). To avoid nonspecific protein- 
protein or protein-cell interactions, all solutions were 
supplemented with the nonionic detergent Brij 35 at a 
concentration of 0.05%. As the amount of added prokal- 
likrein increased, the level of binding increased until sat- 
uration was observed at -25 nM prokallikrein with 
approximately 5 pmol prokallikrein bound per 10’ neu- 
trophils, which corresponds to about 3 x 10’ molecules 
of prokallikrein bound per cell. In contrast to prokal- 
likrein binding, no association of r~ombinant mature 
kallikrein to neutrophils was detected, whereas the final 
extent of binding of urinary kallikrein was reduced 40- 
50%. The discrepancy in the binding behaviour of the 
activated tissue kallikrein in recombinant or native form 
is due to the proenzyme content of kallikrein isolated 
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Fig. 1. ~oncentration~e~ndent binding of different human tissue kallikrein species to human white blood cells. Neutrophils @) and lymphocytes 
(0) at a concentration of 3 x lo7 cells/ml each were incubated with various concentrations of (A) recombinant salivary-gland prokallikrein, 
(B) recombinant salivary-gland kallikrein and (C) native urinary kallikrein for 1 h, respectively. The plotted data represent otal binding. 
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Fig. 2. Time course of binding of human recombinant prokallikrein to 
neutrophils. Isolated human neutrophils (3 x lO’/ml) were incubated in 
the presence of 12 nM (0) or 24 nM (0) salivary-gland prokallikrein, 
respectively and total binding was determined as described in the text. 
from human urine which accounts for between 40% and 
60% of the total kallikrein [13]. 
To show that the binding observed was specific for 
neutrophils, and was not due to some common property 
of cell membranes, binding of the available kallikrein 
species to washed lymphocytes were studied (Fig. 1). 
Equal numbers of lymphocytes and neutrophils were 
used. Although the volume of neutrophil cells is approx- 
imately twice as big than the volume of unstimulated 
lymphocytes, the differences in the surface areas of both 
cell types are insignificant. In respect of this assumption, 
nine times as much recombinant proenzyme bound in the 
neutrophil samples as in the lymphocyte samples, while 
binding of recombinant kallikrein was undetectable in 
any case. Thus, the binding of prokallikrein appears to 
be specific for neutrophils. The values for binding of 
urinary kallikrein to lymphocytes are attributed to the 
above-mentioned prokallikrein portion of the enzyme 
preparation. The kallikrein-neutrophil interaction is re- 
stricted to the association of the proenzyme but it re- 
mains to be elucidated whether the short activation pep- 
tide of seven amino acids or an epitope exposed by the 
three-dimensional structure of the zymogen is responsi- 
ble for cell binding. 
To draw preliminary conclusions about the binding 
type, the association kinetics of prokallikrein to human 
neutrophils was investigated. Binding assays were per- 
formed with prokallikrein concentrations of 12 and 24 
nM, respectively, and sampled at various times. Fig. 2 
shows that the binding of prokallikrein to neutrophils 
was time-dependent and apparent equilibrium for 
saturable binding was not reached before one hour of 
incubation in the case of 24 nM prokallikrein. Lower 
prokallikrein concentrations prolonged the time course 
of association. The observed slow-binding kinetic is con- 
trary to the association time course of the kallikrein 
substrate HMWK to neutrophils reaching the plateau of 
binding after 15-20 min [6]. Together, these data suggest 
that neutrophil binding of tissue prokallikrein does not 
occur through a preshaped receptor molecule but re- 
quires the complex formation with an acquired cofactor. 
This proposed binding mechanism is shown in the case 
of plasma prokallikrein where HMWK acts as the zymo- 
gen carrier on the circulating human neutrophil [8]. 
In summary, our results demonstrate for the first time 
that tissue prokallikrein specifically binds to intact 
human neutrophils and structural features of the zymo- 
gen are required for the interaction with unoccupied sites 
on the neutrophil surface. The presented data preclude 
a direct binding of mature kallikrein to neutrophils mod- 
ifying the previously published hypothesis [9] of 
kallikrein endocytosis by neutrophils with regard to an 
internalization step of prokallikrein. The observed pref- 
erence of the kallikrein precursor is a strong indication 
that indispensable proenzyme conversion to activated 
kallikrein plays an important role in the regulation of 
kallikrein bioactivity. 
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